Heartflow (NASDAQ:HTFL) Price Target Raised to $45.00

Heartflow (NASDAQ:HTFL) had its price objective hoisted by equities researchers at JPMorgan Chase & Co. from $35.00 to $45.00 in a research note issued on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 10.81% from the stock’s previous close.

HTFL has been the topic of several other research reports. Morgan Stanley set a $40.00 target price on Heartflow in a research note on Friday. Weiss Ratings upgraded shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. Robert W. Baird set a $45.00 price objective on shares of Heartflow in a research note on Friday. Freedom Capital upgraded shares of Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. Finally, Piper Sandler reissued an “overweight” rating and set a $45.00 price target on shares of Heartflow in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $43.43.

Heartflow Stock Up 31.0%

Heartflow stock traded up $9.60 during mid-day trading on Friday, hitting $40.61. The company had a trading volume of 5,853,545 shares, compared to its average volume of 1,448,343. Heartflow has a 1 year low of $20.13 and a 1 year high of $42.95. The business has a fifty day moving average of $28.80 and a 200 day moving average of $27.70. The stock has a market cap of $3.50 billion and a price-to-earnings ratio of -13.13.

Heartflow (NASDAQ:HTFL) last issued its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.15. The company had revenue of $64.08 million during the quarter. The firm’s revenue was up 47.7% on a year-over-year basis. Equities analysts anticipate that Heartflow will post -0.82 earnings per share for the current year.

Insider Activity

In other news, CEO John C.M. Farquhar sold 38,900 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $35.00, for a total transaction of $1,361,500.00. Following the transaction, the chief executive officer directly owned 457,935 shares in the company, valued at $16,027,725. This represents a 7.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 9,219 shares of the company’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $28.34, for a total value of $261,266.46. Following the sale, the insider owned 78,731 shares of the company’s stock, valued at $2,231,236.54. This represents a 10.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 115,805 shares of company stock worth $3,530,609 over the last quarter. 7.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in HTFL. XXEC Inc. purchased a new stake in shares of Heartflow in the second quarter worth about $2,524,764,000. Wellington Management Group LLP raised its holdings in shares of Heartflow by 20.8% during the 4th quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock valued at $171,812,000 after buying an additional 1,014,006 shares during the period. BlackRock Inc. acquired a new stake in Heartflow in the second quarter valued at approximately $152,502,000. Bamco Inc. NY lifted its position in shares of Heartflow by 86.2% during the fourth quarter. Bamco Inc. NY now owns 2,303,877 shares of the company’s stock worth $67,158,000 after purchasing an additional 1,066,371 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Heartflow by 152.0% in the first quarter. Janus Henderson Group PLC now owns 2,180,976 shares of the company’s stock valued at $53,063,000 after purchasing an additional 1,315,416 shares during the period.

More Heartflow News

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Strong Q2 performance: Heartflow reported a loss of $0.07 per share, beating the $0.22 expected loss by $0.15. Revenue reached $64.08 million, an increase of 47.7% from the prior-year quarter. Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
• Positive Sentiment: Raised 2026 outlook: Management now expects full-year revenue of $246 million to $250 million, well above the approximately $230.1 million analyst consensus. The higher forecast reinforces expectations for continued demand for Heartflow’s AI-based coronary artery disease diagnostic technology.
• Positive Sentiment: Analyst upgrade: Stifel Nicolaus raised its price target from $40 to $45 and upgraded the stock to “Buy,” implying additional upside based on the reported reference price. This adds further momentum following the earnings release. Benzinga
• Neutral Sentiment: Profitability remains a concern: Although the quarterly loss was narrower than expected and significantly improved from the prior year, Heartflow remains unprofitable. Analysts currently expect a full-year loss of approximately $0.82 per share.
• Negative Sentiment: CEO stock sale: Chief Executive John C.M. Farquhar sold 22,562 shares valued at approximately $638,730, reducing his direct holdings by 4.92%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which reduces its signaling value, but repeated insider selling could still weigh modestly on sentiment. Heartflow CEO Sells Shares

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.